Liu Qing, Li Qingrui, Han Ting, Hu Tingting, Zhang Xuemei, Hu Junhua, Hu Hui, Tan Wen
School of Bioscience & Bioengineering, South China University of Technology.
Institute of Biomedical & Pharmaceutical Sciences, Guangdong University of Technology.
Biol Pharm Bull. 2017 Sep 1;40(9):1374-1380. doi: 10.1248/bpb.b17-00067. Epub 2017 Jun 24.
Currently, all commercial available nebulized salbutamol in China is in its racemic form. It is known that only R-salbutamol (eutomer) has therapeutic effects, while S-salbutamol (distomer) may exacerbate asthma after chronic use. Therefore, it is an unmet clinical need to develop R-salbutamol as a nebulized product that is more convenient for young and old patients. In our study, a stable aerosol solution of R-salbutamol sulfate was established, and its antiasthmatic effects were confirmed. The decomposition rate and racemization effect of the R-salbutamol sulfate solution were evaluated over a pH range from 1 to 10 (except pH=7, 8) at 60°C. The aerodynamic particle size of the R-salbutamol sulfate solution and commercial RS-salbutamol sulfate solution were both tested in vitro by Next-Generation Impactor (NGI) in 5°C. Laser diffractometer was used to characterize the droplet-size distribution (DSD) of both solutions. We next conducted an in vivo animal study to document the antiasthmatic effect of R-salbutamol aerosol sulfate solution and determine the relationship to RS-salbutamol. The results showed that the R-salbutamol sulfate solution was more stable at pH 6. In vitro comparison studies indicated that there was no distribution difference between R-salbutamol sulfate solution and the commercial RS-salbutamol solution. The animal results showed that R-salbutamol was more potent than RS-salbutamol against the same dose of histamine challenge. Unlike commercial RS-salbutamol, which was acidified to a pH of 3.5 to extend bench life but may cause bronchoconstriction in asthmatic patients, the neutralized R-salbutamol solution was more suitable for clinic use.
目前,中国市场上所有可商购的雾化用沙丁胺醇均为消旋体形式。已知只有R-沙丁胺醇(优体)具有治疗作用,而S-沙丁胺醇(劣体)长期使用后可能会加重哮喘。因此,开发一种对老年和年轻患者更方便使用的雾化用R-沙丁胺醇产品是一项未满足的临床需求。在我们的研究中,建立了一种稳定的硫酸R-沙丁胺醇气雾剂溶液,并证实了其抗哮喘作用。在60°C下,对pH值范围为1至10(pH = 7、8除外)的硫酸R-沙丁胺醇溶液的分解速率和消旋化效果进行了评估。在5°C下,通过下一代撞击器(NGI)在体外测试了硫酸R-沙丁胺醇溶液和市售消旋硫酸沙丁胺醇溶液的空气动力学粒径。使用激光衍射仪表征两种溶液的液滴尺寸分布(DSD)。接下来,我们进行了一项体内动物研究,以记录硫酸R-沙丁胺醇气雾剂溶液的抗哮喘作用,并确定其与消旋硫酸沙丁胺醇的关系。结果表明,硫酸R-沙丁胺醇溶液在pH 6时更稳定。体外比较研究表明,硫酸R-沙丁胺醇溶液与市售消旋硫酸沙丁胺醇溶液之间没有分布差异。动物实验结果表明,在相同剂量的组胺激发试验中,R-沙丁胺醇比消旋硫酸沙丁胺醇更有效。与市售消旋硫酸沙丁胺醇不同,后者酸化至pH 3.5以延长保质期,但可能会导致哮喘患者支气管收缩,而中和后的R-沙丁胺醇溶液更适合临床使用。